Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy

Journal of Biomarkers
Charles E RengifoEnrique Rengifo Calzado

Abstract

Adequate methods to identify which lung cancer patients are most likely to benefit from the targeted drugs against both epidermal growth factor receptor/epidermal growth factor (EGFR/EGF) are needed. For this reason, we evaluated both the tissue reactivity of ior egf/r3 monoclonal antibody (Mab) in human lung carcinomas and its biological activity in NCI-H125 cells. Additionally, we assessed the tissue expression of EGF using two Mabs, CB-EGF1 and CB-EGF2. The overexpression of EGFR was detected in 33.33% and 62.71% of small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), respectively. The ability of ior egf/r3 Mab to bind the extracellular domain of EGFR inhibiting cell proliferation and inducing apoptosis in NCI-H125 cells was also demonstrated. The EGF expression was observed in about 17% and 70% of SCLC and NSCLC, respectively. However, differences in the reactivity of CB-EGF1 and CB-EGF2 were evidenced. A dual expression of EGFR and EGF was observed in 16.67% and 57.63% of SCLC and NSCLC patients, respectively. But, a correlation between them was only obtained in NSCLC. Our results permit to recommend the development of diagnostic kits using ior egf/r3 and/or CB-EGF1 Mabs in order to achieve a better ...Continue Reading

References

Mar 1, 1997·Immunotechnology : an International Journal of Immunological Engineering·C MateoR Pérez
Sep 19, 2002·International Journal of Cancer. Journal International Du Cancer·Tania Crombet-RamosAlicia Viloria-Petit
Jul 18, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fred R HirschWilbur A Franklin
Sep 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fred R HirschWilbur A Franklin
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G SelvaggiG V Scagliotti
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Giorgio V ScagliottiFred R Hirsch
May 26, 2007·Applied Immunohistochemistry & Molecular Morphology : AIMM·Mercedes Cedeño-AriasTeresita Rodríguez
Feb 28, 2008·Current Opinion in Oncology·Paul Wheatley-Price, Frances A Shepherd
Mar 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elia Neninger VinagerasAgustín Lage Dávila
Apr 5, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Giaccone, P A Zucali
Jan 14, 2009·Cancer Prevention Research·Adi F Gazdar, John D Minna
Jul 25, 2009·Expert Opinion on Biological Therapy·William Kells Boland, Gwyn Bebb
May 11, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hye Jin ChoiJoo Hang Kim
Aug 5, 2010·British Journal of Cancer·K SchmidW Sieghart
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J VansteenkisteP De Leyn

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

ModFit LT
CellQuest

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis